{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"33","value":"730"},{"groupId":"OG001","spread":"116","value":"534"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"Cycle 1, Day 1"},{"categories":[{"measurements":[{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as there were only two participants. Individual values reported: 373.72 ng\\*h/mL and 3373.97 ng\\*h/mL.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"100","value":"757"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"title":"Cycle 2, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"PK: (AUC0-tlast) was reported.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"All part A participants who received 70 mg/m² abemaciclib were included under this arm.","id":"OG000","title":"Part A: 70 mg/m² Abemaciclib"},{"description":"All part A participants who received 55 mg/m² abemaciclib were included under this arm.","id":"OG001","title":"Part A: 55 mg/m² Abemaciclib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants in Part A who received at least one dose of abemaciclib and had evaluable PK data. Per planned analysis, PK analysis was performed as per the dose of study drug received.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)","title":"Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Tlast (AUC0-tlast) of Abemaciclib in Part A","type":"PRIMARY","unitOfMeasure":"nanogram *hour per milliliter (ng*h/mL)"}